A Study of Short-course Hypofractionated Online-adaptive Radiotherapy for the Post-operative Treatment of Endometrial Cancer: Tolerability and Feasibility (SHORTEN)

Short-course Hypofractionated Online-adaptive Radiotherapy for the Treatment of ENdometrial Cancer

The goal of this clinical trial is to assess the safety and feasibility of using a new form of radiotherapy technology, known as CT online-adaptive radiotherapy, to reduce the number of treatment sessions required in post-operative radiotherapy for patients with endometrial cancer, from 25 sessions over 5 weeks to 5 sessions over a week and a half.

The main questions it seeks to answer are:

• If it is safe to deliver the radiotherapy in a smaller number of treatment sessions with a larger dose per session by utilising the CT online-adaptive technology
• If it is feasible for this treatment to be delivered using the CT online-adaptive technology in a clinical trial All participants who enrol in the study would be offered the trial treatment of the radiotherapy being delivered in 5 sessions. Any potential participants who are subsequently found to be ineligible during the radiotherapy planning process would be excluded from the trial treatment of a higher dose over 5 sessions, but would still be offered the CT online-adaptive technology over 25 sessions outside of the trial.

Participants would undergo the trial treatment with the radiotherapy being delivered in 5 sessions over a week and a half using the CT online-adaptive technology, with any issues during the treatment delivery recorded, and a questionnaire to complete at the end of treatment to see how the new technology was tolerated by participants.

Participants will have their side effects recorded by the trial team before, during and after their treatment for 2 years following the radiotherapy. During this time period participants will also be asked to complete patient questionnaires to assess their perception of side effects and their quality-of-life after undergoing the treatment. Participants will also have blood tests before, during and after the radiotherapy for 3 months to check for any potential problems with blood counts as a result of the trial treatment.

During the 2 years of follow-up after the radiotherapy, participants will also have assessments for if the cancer has returned, which will be completed by a combination of clinical examination, and CT scans.

Following completion of the 2 years of trial follow-up, participants would remain on general follow-up to assess for if the cancer has returned, or for any longer term side effects for up to 5 years after the treatment, but this follow-up will be outside of the trial without the request for ongoing completion of participant questionnaires.

Study Overview

• Status: Not yet recruiting
• Conditions: Endometrial Carcinoma (EC)
• Intervention / Treatment: Radiation: Hypofractionated CT online adaptive radiotherapy (CT-OART) with dose of 30 Gray in 5 fractions, over one and a half weeks

Detailed Description

Background and Rationale Endometrial cancer treatment often requires a multi-modality approach, with patients usually treated with up-front surgical resection followed by a combination of adjuvant chemotherapy, adjuvant external beam radiotherapy (EBRT), and vaginal vault brachytherapy. During EBRT, the target treatment area includes the mobile vaginal vault, necessitating large clinical target volume (CTV) to planning target volume (PTV) margins (10 to 15 mm) of the vaginal vault to account for daily interfraction motion. These large margins lead to significant radiation dosage to the adjacent bladder, rectum, and bowel, which increases the risk of toxicity.

While hypofractionation offers resource and health-economic advantages, its use in endometrial cancer has historically been limited due to the large fields required and the associated risks of late adverse normal tissue effects. However, Online-Adaptive Radiotherapy (OART) allows for the daily re-definition of targets and surrounding organs, and daily replanning, whilst the patient remains on the treatment couch. By mitigating interfraction motion, CT-based OART (CT-OART) can safely reduce the CTV to PTV margins, making the delivery of a hypofractionated dose feasible. This trial leverages CT-OART to test the safety and feasibility of a shortened, ultra-hypofractionated treatment course for post-operative radiotherapy in endometrial cancer.

Study Aims The primary aim is to determine the safety of a shortened ultra-hypofractionation regimen of 30 Gray in 5 fractions, delivered via a CT-OART approach for the post-operative treatment of endometrial cancer.

Secondary aims include determining the feasibility of this ultrahypofractionated regimen on a CT-online adaptive platform, assessing clinician and patient-reported acute toxicity up to 12 weeks following completion of radiotherapy, and late toxicity up to 2 years following completion of radiotherapy, assessing patient-reported quality-of-life up to 2 years following completion of radiotherapy, and assessing overall survival (OS), disease-free survival (DFS) and pelvic relapse-free survival (PRFS) up to 2 years following completion of radiotherapy.

Study Design The SHORTEN trial is a single-site, single-arm, non-blinded Phase IIA trial (R-IDEAL framework). The study aims to recruit 30 adult participants with fully resected endometrial cancer and an indication for post-operative external beam radiotherapy.

All participants who consent to the trial will receive an experimental ultra-hypofractionation regimen of 30 Gray in 5 fractions. This treatment will be delivered on alternate weekdays utilizing a CT-online adaptive radiotherapy platform. Participants are permitted to receive adjuvant sequential chemotherapy either before or after radiotherapy, and vaginal vault brachytherapy boost if clinically indicated, but concurrent chemoradiotherapy is an exclusion criterion.

Treatment Pathway and Follow-up Eligible participants will have a baseline CT Thorax Abdomen and Pelvis (CT-TAP / CT-CAP) to exclude metastatic disease prior to trial participation, and baseline blood tests. In participants who have undergone chemotherapy prior to planned radiotherapy there will be a repeat blood test planned within 7 days of beginning trial radiotherapy. Clinician-assessed (CTCAE 6.0) and patient-assessed toxicity (PRO-CTCAE), patient-reported quality-of-life (EORTC QLQ-C30 & EN24 Module, ED-5D-5L) will be recorded at baseline.

Participants will undergo an offline radiotherapy planning CT scan, which will be used to outline and plan radiotherapy. If there is a significant concern from baseline anatomy on the planning CT scan that organ of interest constraints cannot be met, then patients will either be offered a second planning CT scan, or excluded from trial participation at this point. These patients would still endeavour to be offered CT-OART outside of the trial framework with radiotherapy delivered with standard dose-fractionation over 25 sessions. The number of participants excluded at this point in the trial would be retained for reporting.

For CT-OART process, an on-set CT scan obtained at the beginning of each online session will be used for repeat target and organ of interest contouring, online planning and plan approval. A second CT scan will be taken immediately prior to treatment to verify participant positioning and perform any adjustments as necessary. Immediately following completion of treatment, a third CT scan will be performed to assess for possible participant movement during treatment delivery. All timings of the workflow, and any problems or unexpected events during radiotherapy delivery will be recorded. Participants will also complete an OART tolerability questionnaire on the last day of radiotherapy. Clinician-assessed toxicity (CTCAE 6.0) will be recorded at the end of the first week of radiotherapy, and on the last-day of radiotherapy. On the last day of radiotherapy, patient-reported toxicity (PRO-CTCAE), patient-reported quality-of-life (EORTC QLQ-C30 & EN24, EQ-5D-5L) will also be recorded and a blood test for full blood count (FBC) undertaken.

Follow-up following completion of radiotherapy will be at 2 weeks, 5 weeks, 12 weeks, 6 months, 9 months, 12 months, 16 months, 20 months and 24 months, with visit windows permitted. Emergent toxicity assessed outside of these timepoints will be recorded at the nearest timepoint visit. Clinician-assessed and patient-reported toxicity (PRO-CTCAE) will be assessed at all visits. At the 2, 5 and 12-week visit quality-of-life (EORTC QLQ-C30 & EN24, EQ-5D-5L) questionnaires will be undertaken alongside repeat blood tests (FBC). A clinical examination for recurrence, and response assessment scan (CT-TAP) will also be undertaken at the 12-week appointment. Thereafter a clinical examination will be completed at the 6-month, 9-month, 12-month, 16-month, 20-month and 24-month visit, with CT-TAP and Quality-of-life questionnaires at the 12-month and 24-month visit.

Diagnosis of recurrence can be made from radiological findings consistent with recurrence, tissue biopsy or cytological specimen, or concerning clinical examination features subsequently confirmed to represent disease recurrence. If a participant experiences disease recurrence during the trial period, they will be managed as per standard management relevant to site and stage of recurrence. As recurrence may necessitate treatment which may impact upon validity of assessment of post-radiotherapy toxicity, then they will not be included within analyses from the point of recurrence, and questionnaire completion will also cease at this time-point.

Participants may withdraw from study participation at any time. If this is due to poor tolerability of CT-OART then aim would be for participant to complete radiotherapy with standard dose-fractionation on conventional linear accelerator. They would continue within trial follow-up population unless they also wish to discontinue trial involvement fully. Participants may be withdrawn by trial investigators due to attributable grade 4 (CTCAE 6.0) toxicity occurring during the radiotherapy course, an inability to safely tolerate CT-OART, or for an unexpected machine breakdown precluding completion of radiotherapy course in a timely manner. These participants would remain within trial analysis population, other than for the primary endpoint (unless radiotherapy was stopped early due to grade 4 toxicity in which case they would be included within the analysis population).

The end of the trial will be the date of the last visit, at 2 years following completion of radiotherapy, of the last trial participant.

• Study Type: Interventional
• Enrollment (Estimated): 30
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Benjamin James Thomas, Clinical Research Fellow; Phone Number: +442086426011; Email: SHORTEN.trial@rmh.nhs.uk
• Study Contact Backup: Name: Kylie Fitch, Trial Manager; Phone Number: +442086426011; Email: SHORTEN.trial@rmh.nhs.uk

Study Locations

• United Kingdom
  • Sutton, United Kingdom, SM2 5PT
    • The Royal Marsden Hospital - Sutton
    • Contact: Benjamin James Thomas, Clinical Research Fellow; Phone Number: +442086426011; Email: SHORTEN.trial@rmh.nhs.uk
    • Contact: Kylie Fitch, Trial Manager; Phone Number: +442086426011; Email: SHORTEN.trial@rmh.nhs.uk
    • Principal Investigator: Susan Lalondrelle, Consultant Clinical Oncologist

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion criteria

1. Histologically confirmed endometrial carcinoma - inclusive of endometrioid adenocarcinoma, carcinosarcoma, clear cell carcinoma, serous carcinoma, dedifferentiated carcinoma, mucinous carcinoma, mixed carcinoma
2. Age greater than 18 years old
3. Disease fully resected at time of surgery
4. Indication for post-operative external beam radiotherapy: high-intermediate risk and high-risk disease (ESGO-ESTRO-ESP guideline), or at the discretion of treating Clinical Oncologist
5. If adjuvant systemic chemotherapy is indicated, participants will still be eligible for trial participation, provided there is a minimum 3-week gap between completing chemotherapy and beginning external beam radiotherapy
6. If adjuvant vaginal vault brachytherapy boost is indicated, participants will still be eligible for trial participation, with a minimum gap of 1 day from completion of external beam radiotherapy to first fraction of brachytherapy
7. WHO Performance Status 0 - 2
8. Informed written consent

Exclusion criteria

1. Previous pelvic radiotherapy
2. Contraindication to receiving external beam radiotherapy
3. Residual disease identified on post-operative imaging
4. FIGO 2023 Stage 3C2 disease requiring extended para-aortic treatment field
5. Hip prostheses or other metal work within the imaging field which would produce significant imaging artifact
6. Indication for adjuvant concurrent chemo-radiotherapy

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: Single-arm - Hypofractionated online-adaptive radiotherapy 30Gy/5# via CT-OART; Single-arm - All 30 patients to undergo experimental arm of hypofractionated online-adaptive radiotherapy for the post-operative treatment of endometrial cancer with a dose of 30 Gray in 5 fractions, delivered on alternate weekdays over a week and a half duration, via a CT-online adaptive approach (CT-OART)

Radiation: Hypofractionated CT online adaptive radiotherapy (CT-OART) with dose of 30 Gray in 5 fractions, over one and a half weeks; Hypofractionated CT online adaptive radiotherapy (CT-OART) with dose of 30 Gray in 5 fractions, over one and a half weeks, for the post-operative treatment of endometrial cancer

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage of patients experiencing acute grade 3 or 4 gastrointestinal or genitourinary toxicity, attributable to radiotherapy	• Percentage of patients experiencing acute grade 3 or 4 gastrointestinal or genitourinary toxicity, attributable to radiotherapy, up to 12 weeks following radiotherapy (as assessed by National Cancer Institute Clinician graded Common Terminology Criteria for Adverse Events (CTCAE) 6.0)	From beginning radiotherapy, up to 12 weeks following completion of radiotherapy

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Feasibility of a CT Online Adaptive workflow	Feasibility of a CT-online adaptive workflow, as assessed by: Patient-experience questionnaire at the end of radiotherapy (Likert scale 0 - 3 where 0 represents a negative response and 3 the most favourable response) , greater than 80% of scheduled CT-OART fractions delivered, Narrative of workflow delays and issues, Patient in room to out of room timing	From Day 1 of radiotherapy treatment course, assessed at every treatment fraction for all 5 treatment fractions, up to and inclusive of final 5th radiotherapy fraction (an average duration of 10 days)
Patient-reported acute GI and GU toxicity incidence, severity, and longitudinal change from baseline up to 12 weeks following radiotherapy	Patient-reported acute GI and GU toxicity incidence, severity, and longitudinal change from baseline up to 12 weeks following radiotherapy, as assessed by the Patient-Reported Outcome Common Terminology Criteria for Adverse Events (PRO-CTCAE), on a 0 to 4 scale, where 0 reports no symptoms and 4 reports maximum symptom severity, frequency or life interference	From beginning radiotherapy, up to 12 weeks following completion of radiotherapy
Percentage of patients experiencing all acute grade 2 + toxicity, including haematological toxicity, attributable to radiotherapy, up to 12 weeks following radiotherapy	Percentage of patients experiencing all acute grade 2 + toxicity, including haematological toxicity, attributable to radiotherapy, up to 12 weeks following radiotherapy, as assessed by CTCAE 6.0	From beginning radiotherapy, up to 12 weeks following completion of radiotherapy
Percentage of patients experiencing all acute grade 3 / 4 toxicity, including haematological toxicity, attributable to radiotherapy, up to 12 weeks following radiotherapy	Percentage of patients experiencing all acute grade 3 / 4 toxicity, including haematological toxicity, attributable to radiotherapy, up to 12 weeks following radiotherapy, as assessed by CTCAE 6.0	From beginning radiotherapy, up to 12 weeks following completion of radiotherapy
Percentage of patients experiencing all late grade 2 + toxicity, attributable to radiotherapy, up to 2 years following radiotherapy	Percentage of patients experiencing all late grade 2 + toxicity, attributable to radiotherapy, up to 2 years following radiotherapy, as assessed by CTCAE 6.0	From beginning radiotherapy, up to 2 years following completion of radiotherapy
Patient-reported late GI and GU toxicity incidence, severity, and longitudinal change from baseline up to 2 years following radiotherapy	Patient-reported late GI and GU toxicity incidence, severity, and longitudinal change from baseline up to 2 years following radiotherapy, as assessed by PRO-CTCAE, on a 0 to 4 scale, where 0 reports no symptoms and 4 reports maximum symptom severity, frequency or life interference	From beginning radiotherapy, up to 2 years following completion of radiotherapy
Change in patient-reported quality-of-life scoring from baseline up to 2 years following radiotherapy - EORTC QLQ-C30	Change in patient-reported quality-of-life scoring from baseline up to 2 years following radiotherapy, as assessed by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-C30)	From beginning radiotherapy, up to 2 years following completion of radiotherapy
Change in patient-reported quality-of-life scoring from baseline up to 2 years following radiotherapy - EORTC QLQ-EN24	Change in patient-reported quality-of-life scoring from baseline up to 2 years following radiotherapy, as assessed by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Endometrial-Cancer Module (EORTC QLQ-EN24)	From beginning radiotherapy, up to 2 years following completion of radiotherapy
Change in patient-reported quality-of-life scoring from baseline up to 2 years following radiotherapy - EQ-5D-5L	Change in patient-reported quality-of-life scoring from baseline up to 2 years following radiotherapy, as assessed by the EuroQol 5 Dimensions, 5 Level version (EQ-5D-5L)	From beginning radiotherapy, up to 2 years following completion of radiotherapy
Overall survival	Overall survival up to 2 years from start of radiotherapy	Up to 2 years from start of radiotherapy
Disease-free survival	Disease-free survival up to 2 years from start of radiotherapy	Up to 2 years from start of radiotherapy
Pelvic relapse-free survival	Pelvic relapse-free survival up to 2 years from start of radiotherapy	Up to 2 years from start of radiotherapy

Collaborators and Investigators

• Sponsor: Royal Marsden NHS Foundation Trust
• Investigators: Principal Investigator: Susan Lalondrelle, Consultant Clinical Oncologist, Royal Marsden NHS Foundation Trust

Study record dates

Study Major Dates

• Study Start (Estimated): August 1, 2026
• Primary Completion (Estimated): May 1, 2028
• Study Completion (Estimated): May 1, 2030

Study Registration Dates

• First Submitted: June 12, 2026
• First Submitted That Met QC Criteria: June 23, 2026
• First Posted (Actual): June 30, 2026

Study Record Updates

• Last Update Posted (Actual): June 30, 2026
• Last Update Submitted That Met QC Criteria: June 23, 2026
• Last Verified: June 1, 2026

More Information

Terms related to this study

• Keywords: Hypofractionation; Endometrial; Online Adaptive Radiotherapy; Ultrahypofractionation; CT Online Adaptive Radiotherapy
• Additional Relevant MeSH Terms: Urogenital Diseases; Genital Diseases; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Uterine Diseases; Genital Diseases, Female; Genital Neoplasms, Female; Uterine Neoplasms; Endometrial Neoplasms
• Other Study ID Numbers: CCR6365

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: De-identified individual participant data, from those participants who consent (optional consent on the trial consent form) to data-sharing will be made available to qualified researchers upon reasonable request following publication of primary analysis and late secondary endpoints. Requests must be submitted via a formal Data Access Request form to the Sponsor. Data sharing will only be undertaken for projects with a sound scientific rationale and patient benefit, subject to approval via the CI, TMG, Sponsor and execution of a formal Data Sharing Agreement
• IPD Sharing Supporting Information Type: STUDY_PROTOCOL

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No